BioSpace News Archive

Mr. Fanelli joins the Theralink team having previously held positions at Metabolon Inc., Core Diagnostics, Nanostring Technologies and Bio-Rad Laboratories

Tivity Health, Inc. (Nasdaq: TVTY) today announced that its financial results for the second quarter ending June 30, 2020, will be released after market close on Wednesday, August 5, 2020, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. ET

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today recognizes Glioblastoma (GBM) Awareness Day.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the completion of dosing for the Phase 1 multiple ascending dose (“MAD”) clinical study for RGLS4326 in healthy volunteers.

Nutriband Inc., a Nevada Corporation has announced that the application for its ‘AVERSA’ Trademark in relation to its abuse deterrent technology and lead product candidate has passed the examination and third party opposition phase and the company expects to receive a notice of allowance in due time.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA®

Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 5, 2020 to report its second quarter 2020 financial results and provide a corporate update. To access the live confer

– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech – – Managing Partner at Kleiner Perkins Caufield & Byers China; Founder of Panacea Venture, funding source for Ziopharm’s joint venture Eden BioCell –

Zelira Therapeutics Ltd ( ASX: ZLD) (OTCQB: ZLDAF ), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based

The Hematology/Oncology Pharmacy Association (HOPA) and Horizon CME (HCME) jointly announce their collaboration to provide BCOP accredited education to oncology pharmacists through HCME’s Advanced Practice Provider Oncology Summit (APPOS) series